Torrent Pharma Gears Up to Launch Oral, Injectable Semaglutide in 2026 Post Patent Expiry: Report
New Delhi: Torrent Pharmaceuticals is preparing to introduce both oral and injectable versions of Semaglutide, a blockbuster diabetes and weight loss drug, currently led by Danish pharmaceutical giant Novo Nordisk, following its patent expiry in India in early 2026, according to recent media reports.
While Novo Nordisk holds the current monopoly over the molecule in India, generic drugmakers are actively eyeing opportunities post-patent expiry. Torrent is among the early movers preparing for this high-stakes market entry.
Semaglutide, a GLP-1 receptor agonist, is the active ingredient in Novo Nordisk’s globally popular brands Ozempic, Wegovy, and Rybelsus, used to manage type 2 diabetes and obesity. The drug has seen a massive surge in demand worldwide, including in India, driven by its dual action on blood sugar and body weight.
Also Read: After Much Tussle, Torrent Pharma Clinches JB Chemicals Deal At Rs 25,689 Cr Valuation
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.